Professor Sir Nicholas J White
Podcast interview
Artemisinin therapy for malaria
Malaria kills more than half a million people every year. Following a number of groundbreaking clinical trials, Professor Sir Nick White and his Thailand team successfully demonstrated the effectiveness of artemisinin drug therapy for malaria in adults, children and infants. He also pioneered artemisinin combination therapy, the first-line treatment for malaria worldwide.
Research groups
Colleges
Nicholas White
FRS
Professor of Tropical Medicine
- Professor at Mahidol University in Thailand
Professor White’s diverse interests include the epidemiology, pathophysiology and management of uncomplicated and severe malaria, meliodosis, enteric fever, tetanus, dengue haemorrhagic fever, Japanese encephalitis and tuberculosis. His particular interests at present include the pathophysiology and treatment of severe malaria, the prevention of antimalarial drug resistance using artemisinin-based combinations. and the biology of relapse in vivax malaria.
Vivax malaria
Recent publications
-
What causes malaria anemia?
Journal article
White NJ., (2022), Blood, 139, 2268 - 2269
-
Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project
Journal article
Chandna A. et al, (2022), Wellcome Open Research, 6, 64 - 64
-
Have we really failed to roll back malaria?
Journal article
White NJ. et al, (2022), Lancet (London, England), 399, 799 - 800
-
Methaemoglobinaemia and the radical curative efficacy of 8‐aminoquinoline antimalarials
Journal article
White NJ. et al, (2022), British Journal of Clinical Pharmacology
-
The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions.
McLean ARD. et al, (2022)